Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Clinical Psychopharmacology

Volumn 38, Issue 2, 2018, Pages 134-137

  Gray, Joshua C ^a,b   Treloar Padovano, Hayley ^a   Wemm, Stephanie E ^a   Miranda, Robert ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

adolescents; cannabis; side effects; tolerability; topiramate

Indexed keywords

PLACEBO; TOPIRAMATE; ANTICONVULSIVE AGENT; FRUCTOSE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANNABIS ADDICTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; ADOLESCENT BEHAVIOR; ANALOGS AND DERIVATIVES; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; PATIENT DROPOUT; PROCEDURES; PSYCHOTHERAPY;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADULT; ANTICONVULSANTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MARIJUANA ABUSE; MEDICATION ADHERENCE; PATIENT DROPOUTS; PSYCHOTHERAPY; YOUNG ADULT;

EID: 85043459486     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000843     Document Type: Article

References (39)

1. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl JMed. 2014; 370: 2219-2227.
2. Davis ML, Powers MB, Handelsman P, et al. Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof. 2015; 38: 94-114.
3. Copeland J, Pokorski I. Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil. 2016; 7: 41-53.
4. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychitary. 2010; 71: 634-648.
5. Miranda RJ, Treloar H, Blanchard A, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addict Biol. 2017; 22: 779-790.
6. Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014; 38: 1481-1488.
7. Oncken C, Arias AJ, Feinn R, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2014; 16: 288-296.
8. Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2017.
9. Singh M, Keer D, Klimas J, et al. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016; 111: 1337-1346.
10. Arnone D, Stifani L, Dam M, et al. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry. 2005; 4: 5.
11. Wandschneider B, Burdett J, Townsend L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology. 2017; 88: 1165-1171.
12. Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Res. 2013; 105: 250-255.
13. Feinn R, Curtis B, Kranzler HR. Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care. J Clin Psychiatry. 2016; 77: e278-e282.
14. Ray LA, Miranda R, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009; 17: 122-129.
15. Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, et al. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013; 33: 1010-1024.
16. Stahler GJ, Mennis J, DuCette JP. Residential and outpatient treatment completion for substance use disorders in the U. S.: moderation analysis by demographics and drug of choice. Addict Behav. 2016; 58: 129-135.
17. Robinson SM, Sobell LC, Sobell MB, et al. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014; 28: 154-162.
18. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986; 22: 343-381.
19. Johnson V, White HR. The relationship between work-specific and generalized stress and alcohol and marijuana use among recent entrants to the labor force. J Drug Issues. 1995; 25: 237-251.
20. White HR, Labouvie EW. Towards the assessment of adolescent problem drinking. J Stud Alcohol. 1989; 50: 30-37.
21. Cox DR. Regression models and life-tables. In: Kotz S, Johnson NL, eds. Breakthroughs in Statistics. New York, NY: Springer; 1992: 527-541.
22. Schuckit MA, Smith TL, Paulus MP, et al. The ability of functional magnetic resonance imaging to predict heavy drinking and alcohol problems 5 years later. Alcohol Clin Exp Res. 2016; 40: 206-213.
23. Lent MR, Hoffman SN, Kirchner HL, et al. Attitudes about future genetic testing for posttraumatic stress disorder and addiction among community-based veterans. Front Psychiatry. 2017; 8: 76.
24. IBM Corp. IBM SPSS Statistics for Windows, Version 22. 0. Armonk, NY: IBM Corp; 2013.
25. Lowry R. Significance of the difference between two correlation coefficients [VassarStats]. 2017. Available at: http://vassarstats. net/rdiff. html. Accessed October 26, 1997.
26. Zhang JT, Ma S-S, Yip SW, et al. Decreased functional connectivity between ventral tegmental area and nucleus accumbens in Internet gaming disorder: evidence fromresting state functionalmagnetic resonance imaging. Behav Brain Funct. 2015; 11: 37.
27. Neacsiu AD, Herr NR, Fang CM, et al. Identity disturbance and problems with emotion regulation are related constructs across diagnoses. J Clin Psychol. 2015; 71: 346-361.
28. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993; 80: 27-38.
29. Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med. 2006; 25: 4216-4226.
30. Dewing S, Tomlinson M, le Roux IM, et al. Food insecurity and its association with co-occurring postnatal depression, hazardous drinking, and suicidality among women in peri-urban South Africa. J Affect Disord. 2013; 150: 460-465.
31. Naughton F, Cooper S, Foster K, et al. Large multi-centre pilot randomized controlled trial testing a low-cost, tailored, self-help smoking cessation text message intervention for pregnant smokers (MiQuit). Addiction. 2017; 112: 1238-1249.
32. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
33. Heinze G, PlonerM, Dunkler D, et al. logistf: Firth's bias reduced logistic regression R package version 1. 21. 2013.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995; 57: 289-300.
35. Gray JC, Amlung MT, Owens M, et al. The neuroeconomics of tobacco demand: an initial investigation of the neural correlates of cigarette cost-benefit decision making in male smokers. Sci Rep. 2017; 7: 41930.
36. Moberg CA, Bradford DE, Kaye JT, et al. Increased startle potentiation to unpredictable stressors in alcohol dependence: possible stress neuroadaptation in humans. J Abnorm Psychol. 2017; 126: 441-453.
37. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014; 171: 445-452.
38. Martinotti G, Di Nicola M, De Vita O, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014; 34: 709-715.
39. Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011; 11: 41.